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The development of breast cancer is influenced by the adipose tissue through the proteins leptin and adiponectin. However, there is
little research concerning AdipoR1 and AdipoR2 receptors and the influence of leptin over them. The objective of this work was to
analyze the expression of AdipoR1 and AdipoR2, modulated by differential concentrations of leptin in an obesity model (10 ng/mL,
100 ng/mL, and 1000 ng/mL) associated with breast cancer in MCF-7 and HCC1937 cell lines. Each cell line was characterized
through immunohistochemistry, and the expression of AdipoR1 and AdipoR2 was analyzed by PCR in real time using
TaqMan® probes. Leptin induced an increase in cell population of MCF-7 (23.8%, 10 ng/mL, 48 h) and HCC1937 (17.24%,
1000 ng/mL, 72 h). In MCF-7, the expression of AdipoR1 decreased (3.81%, 1000 ng/mL) and the expression of AdipoR2
increased by 13.74 times (10 ng/mL) with regard to the control. In HCC1937, the expression of AdipoR1 decreased by 86.28%
(10 ng/mL), as well as the expression of AdipoR2 (50.3%, 100 ng/mL). In regard to the results obtained, it could be concluded
that leptin has an effect over the expression of AdipoR1 and AdipoR2 mRNA.
1. Introduction
Over the last 20 years, the development of breast cancer has
been associated to lifestyle changes, primarily to obesity [1].
Obesity is considered an excess in the accumulation of adi-
pose tissue produced when caloric intake exceeds energy
consumption [2]. Besides storing excess calories in the form
of lipids, the adipose tissue participates through diverse
forms in the development of cancer due to the fact that it also
acts as an endocrine gland, liberating the adipocytokines
leptin and adiponectin and proinflammatory molecules [3].
Leptin is a protein produced from the OB gen or “gen of
obesity” [4]. The expression of the gen is restricted to adipose
tissue, and its levels are closely related to the storage of
triglycerides and the mass of adipose tissue [5]. It is a
pleiotropic adipocytokine which regulates the ingestion of
foods, energy consumption, immunity, inflammation, hema-
topoiesis, cell differentiation, and proliferation [6, 7].
Adiponectin is a protein produced exclusively in white
adipose tissue [8] and is considered as a protection hormone,
carrying out an important role in the regulation of glucose
through a potent sensitizing effect towards insulin, which
affects the uptake of glucose in the muscle and participates
in the homeostasis of lipids [9]. Its plasmatic concentration
has an inversely proportional relationship towards obesity,
body mass index, accumulation of visceral fat, and insulin
resistance [10, 11]. It carries out its function through two spe-
cific receptors, AdipoR1 and AdipoR2, which are receptors
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coupled to G proteins with six transmembrane domains.
AdipoR1 is predominantly expressed in striated muscle,
while AdipoR2 is mainly expressed in the liver [12]. The
bonding of adiponectin to its receptors increases the activity
of the AMP-dependent protein kinase (AMPK) and the
peroxisome proliferator-activated alpha receptor (PPAR-α),
favoring the oxidation of fatty acids and the entrance of
glucose into tissues [13]. The activated AMPK system plays
a vital role in the regulation of the energetic metabolism
and cell quiescence [14, 15].
The pathologies, which modify the biology of adipose
tissue, such as obesity, and produce an alteration in the secre-
tion of these adipocytokines, increasing the liberation of
leptin, VEGF, IL-6, and TNF-α and decreasing the secretion
of adiponectin could be linked to different carcinogenic
mechanisms including cell differentiation, apoptosis, cell
proliferation, angiogenesis, and alteration of steroidal sex
hormone levels [9].
This variation in the secretion of adipocytokines by the
adipose deposits may explain the relationship between
obesity and the development of breast cancer, since obese
subjects present a decrease in the levels of circulating
adiponectin and increase in the plasmatic concentration of
leptin [5, 16].
The aforementioned has been observed in diverse in vitro
experiments, in which the promoting activity of proliferation
in breast cancer cell lines by leptin is mediated through dif-
ferent signal pathways; on one hand, it acts by inducing the
P13K/Akt survival pathway, activating the phosphorylation
of Akt, stimulating protein expression of PKC-alpha, acti-
vating the MAPK pathway, and stimulating ERK1 and
ERK2 [17–20]. It activates the STAT3 pathway and induces
upregulation of c-myc at an mRNA level, as well as at a pro-
tein level. Likewise, it upregulates genes of the cell cycle
(cyclin D1) and reduces the expression of p53 and the
production of Bax [21–23]. Some studies suggest that leptin
may promote angiogenesis in breast cancer through the
signaling of VEGF [24]. In this manner, it can be deduced
that the procarcinogenic effect of leptin derives from the
activation of signaling pathways implicated in the cell prolif-
eration process and a downregulation of the apoptotic
response [25, 26].
Likewise, the antiproliferative action of breast cancer cells
by adiponectin is mediated by an inactivation of protein 1
and 3 expression in MAPK p44/42, a stimulation of AMPK
activity and a decrease in phosphorylation of Akt, associated
with an increased expression of LKB1, reducing the activity
of mTOR and leading to a decrease in the production of
reactive oxygen species [19, 27–29]. Studies suggest that
adiponectin modulates the cell cycle of breast cancer cells,
decreasing the expression of cyclin D1 [30, 31]. In diverse
studies, it has been detected that adiponectin induces cell
apoptosis when a stimulus is given to cell lines with an incu-
bation period longer than 48h [32, 33]. Also, an increase of
PPAR in estrogen-positive cell lines, the downregulation of
Bcl2, and the activation of p53 and Bax have been detected
[34, 35]. Finally, it is suggested that an interaction of adipo-
nectin and estrogen pathways exists, since it is capable of
reducing aromatase and the expression of the receptor [36].
For the identification of the procarcinogenic mecha-
nisms of leptin, the breast cancer cell lines MCF-7,
MDA-MB-231, and T47D have been characterized for
the protein and its receptor [Ob-R), studying its effect over
cell growth in the MCF-7, SK-BR-3, T47D, and ZR-75-1
cell lines. An increase in cell proliferation when the cells
receive a single stimulus of leptin and incubated between
24 and 96h has been observed [21, 27, 28, 37, 38].
In order to better understand the potential involvement
of leptin in the expression of adiponectin receptors, AdipoR1
and AdipoR2, in the cells of breast cancer, the main objective
of this research was to demonstrate that AdipoR1 and Adi-
poR2 were expressed in MCF-7 and HCC1937 breast cancer
cell lines, as well as to determine and analyze the expression
of these receptors modulated by differential concentrations
of leptin [27].
2. Materials and Methods
2.1. Cell Culture. For this study, cell lines MCF-7 and
HCC1937 were employed and were obtained from the
American Type Culture Collection (ATCC). They were cul-
tivated at 37°C in an atmosphere of 5% CO2 and 85%
humidity, with culture medium (RPMI 1640 medium,
Gibco®, Thermo Fisher Scientific™, Dulbecco’s modified
Eagle’s medium, Caisson Labs, USA) supplemented with
10% fetal bovine serum (Gibco, Thermo Fisher Scientific,
USA), inactivated by heat (30min at 57°C; water bath), with
medium exchange every third day.
2.2. Immunohistochemistry. The expression of estrogens
(RE), progesterone (RP), Her2, and Ki67 was determined
through immunohistochemistry. Once a confluence of 70%
of cells was reached, they were washed with PBS (phos-
phate-buffered saline, Gibco, Thermo Fisher Scientific,
USA) and were suspended with 0.05% trypsin (Gibco,
Canada). The recuperated cells were centrifuged for 3min
at 1500 rpm, and the cell pellet was then used to prepare
slides fixed with acetone. Posteriorly, the recuperation of
epitopes was done, utilizing 0.1% sodium citrate (Dako,
USA, pH 6.2), inactivating endogenous peroxidase with
0.9% hydrogen peroxide. The slides were washed with dis-
tilled water and were placed in PBS for 5 minutes [39].
The cells were then incubated during 45 minutes with the
following antibodies: RE 1 : 35 (Dako, USA), RP 1 : 50
(Dako, USA), Her2 1 : 50 (Biocare, USA), and Ki67 1 : 100
(Biocare, USA).
Next, a two-step detection system was incorporated
(Mach 1 Universal HRP-Polymer Detection, Biocare, USA)
during 30 minutes each. The reaction was visualized with
3,3′-diaminobenzidine (Leica Biosystems, USA) and was
stained with Hill’s hematoxylin [39].
2.3. Proliferation Assay. The study of cell proliferation was
carried out through the crystal-violet assay. For this purpose,
two groups of 5000 MCF-7 and HCC1937 cells were inocu-
lated in 96-well culture plates and were left to grow during
24 h (group 1) and 48h (group 2). Afterwards, each group
was washed every 24 h, during 96 h, with PBS and fresh
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culture medium (supplemented with 5% SFB) with leptin
stimuli, which was added (Recom Hu Leptin Active, Sino
Biological, Thermo Fisher Scientific, USA) in concentrations
of 0 ng/mL (negative control), 10 ng/mL, 100ng/mL, and
1000 ng/mL [27]. The decrease of SFB was done to reduce
the growth factors that could interfere with the action of
leptin [40].
Cell proliferation in each cell line was determined in trip-
licate for every concentration evaluated. After 24h of stimu-
lation, the cells were fixed with 1.1% glutaraldehyde (Merck,
Germany) during 15 minutes and then PBS was added until
the 96 h of stimulation with leptin was concluded for each
group. At the end of stimulation, the fixed cells were stained
with crystal-violet for 15 minutes, the plate was washed with
water, and 10% acetic acid was placed in each well. Immedi-
ately after, the plate was read at an excitation wavelength of
490nm and an emission wavelength of 630nm in a micro-
plate reader (Stat Fax 2100 Microplate Reader, Awareness
Technology Inc.)
2.4. Analysis of Microassays. The regulation of gene expres-
sion of adiponectin receptors AdipoR1 and AdipoR2 was
evaluated by means of the addition of leptin to the cell lines
following the methodology proposed by Jardé et al., [27],
with slight modifications. 2000 MCF-7 and HCC1937 cells
were cultured in 24-well culture plates, allowing them to
grow during 48 h.
After 24h, 48 h, 72 h, and 96 h, the cells were washed with
PBS and fresh culture medium (supplemented with 5% SFB)
with leptin stimuli (0 ng/mL, 10 ng/mL, 100ng/mL, and
1000 ng/mL) was added. At the end of the stimulation, the
culture medium was removed and 400μL of TRIzol® reagent
was added to carry out the mRNA extraction, in accordance
with the protocol of use (Ambion™).
Once the mRNA was obtained, the acquisition of the
complementary DNA was carried out (cDNA) from 2μg of
mRNA through the reverse transcriptase reaction, in accor-
dance with the protocol of use (high-capacity RNA to cDNA
kit, Applied Biosystems), obtaining 20μL of cDNA.
The cDNA of the controls of each cell line were used
to determine, through endpoint PCR (HotStarTaq DNA
Polymerase, QIAGEN, Germany), the presence of AdipoR1
mRNA (Fw: 5′-AATTCCTGAGCGCTTCTTTCCT-3′, Rv:
5′-CATAGAAGTGGACAAAGGCTGC-3′) and AdipoR2
mRNA (Fw: 5′-TGCAGCCATTATAGTCTCCCAG-3′, Rv:
5′-GAATGATTCCACTCAGGCCTAG-3′), using the ACTB
control gen (Fw: 5′-GCACCACACCTTCTACAAAG-3′, Rv:
5′-GGTCTCAAACATGATCTGGTC-3′).
Likewise, the cDNA obtained through the stimuli was
used to determine the gene expression of AdipoR1 and Adi-
poR2 through real-time PCR (TaqManUniversalMix II, with
UNG), utilizing TaqMan probes (Gene Expression Assays,
Applied Biosystems) for AdipoR1 (Hs 01114951_ml) and
AdipoR2 (Hs 00226105_ml), using the ACTB gene as a
control (Hs 99999903_ml), following the instructions of the
LightCycler® 2.0 thermocycler (Roche Diagnostics). The pro-
gram utilized to carry out the PCR was 50°C for 2 minutes,
95°C for 10min, 40 cycles at 95°C for 15 seconds, and 60°C
for 1min.
For the determination of relative levels of AdipoR1 and
AdipoR2 gene expression, the Pfafflmethod of relative quan-
tification, based on the comparison of the threshold cycle of
a constitutive gene (mRNA of ACTB) with the test gene of
each sample in duplicate, was carried out. The change in the
fold of AdipoR1 and AdipoR2 was normalized with regard
to the reference genes expressed constitutively and was then
compared with the nontreated controls as follows: 2−ΔΔCT,
where ΔΔCT=ΔΔCT= (CT−target−CT−reference)treated sample−
(CT−target−CT−reference)calibrating sample. “Calibrating sample”
refers to the level of expression (1×) of the target gene
normalized for the constitutive gen. The calibrator was
chosen from the control group of each cell line and was given
a value of 1 for relative expression [41–43].
3. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6
software. To analyze the results of the growth curves of
each cell line, a two-factor ANOVA was performed with a
p value> 0.05, to establish the relationship between incuba-
tion time and leptin concentrations.
For the analysis of gene expression results of AdipoR1
and AdipoR2, we first tested a normality hypothesis using
the Kolmogorov-Smirnov test. Subsequently, the Student’s
t-test was performed for the parametric variables and the
Mann–Whitney U test for the nonparametric variables with
a p value> 0.05 for each one.
4. Results
4.1. Characterization by Immunohistochemistry. The selec-
tion of the cell lines employed in this experiment was done
in accordance with the molecular classification of breast
cancer, in other words, in accordance with the hormonal
receptors that are found expressed by the cells.
Using the immunohistochemistry technique, each cell
line was characterized according to the molecular classi-
fication “triple positive” (MCF-7) and “triple negative”
(HCC1937), evaluating the presence of Ki67, estrogen (RE),
progesterone (RP), and Her2 (Figure 1).
MCF-7, a cell line identified as “triple positive,” had an
expression positive for Ki67 at 78% (78 cells out of 100), RE
at 45% (45 cells out of 100), RP at 5% (5 cells out of 100),
and Her2 at 14% (14 cells out of 100).
In contrast to MCF-7, HCC1937 breast cancer cells
presented an expression negative for RE, RP, and Her2. For
Ki67, they presented an expression positive at 7% (7 cells
out of 100), as shown in Figure 1.
4.2. Expression of Leptin, Adiponectin, AdipoR1, and AdipoR2
in Breast Cancer Cell Lines. The mRNA of leptin and
adiponectin was detected in MCF-7 breast cancer cells
through endpoint PCR, observing a greater expression of
leptin mRNA when compared to adiponectin mRNA, in
accordance with the bands obtained in the electrophoretic
gel, as shown in Figure 2. With regard to HCC1937, a
triple-negative cell line with a mutation in BRCA1 [44],
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it was also possible to determine the expression of these
genes (Figure 2).
As far as AdipoR1 and AdipoR2 mRNA is concerned, it
was detected in MCF-7 and HCC1937 cells through endpoint
PCR. In MCF-7, two adiponectin receptors, AdipoR1 and
AdipoR2, were found to be expressed, just as Jardé et al.
had reported [27]. As in the case of leptin and adiponectin,
HCC1937 expresses these two receptors, a line that was not
found to be reported “positive” in literature (Figure 3).
In both cell lines, the expression of AdipoR2 mRNA
is greater with regard to BACT and AdipoR1 mRNA
expression, in agreement with the bands obtained in the
electrophoretic gel, as can be seen in Figure 3.
Once it was proven that the three cell lines studied
express AdipoR1 and AdipoR2 mRNA, the quantitative
determination of the expression of these receptors through
real-time PCR, utilizing BACT as a control, went underway.
4.3. Effect of Leptin over Cell Proliferation of MCF-7 and
HCC1937 Breast Cancer Cells. In the cells which were
subjected to the leptin stimuli 24 h after culture (group 1), a
negative effect was observed (antiproliferative) in cell
A.1 A.2 A.3 A.4
(a)
B.1 B.2 B.3 B.4
(b)
Figure 1: Characterization through immunohistochemistry of MCF-7 and HCC1937 cells. Detection through immunohistochemistry of the
Ki67 protein, estrogen receptor (ER), progesterone receptor (PR), and Her2 in breast cancer cell lines. MCF-7 expression positive for Ki67
(A.1), ER (A.2), PR (A.3), and Her2 (A.4). HCC1937 cells exhibited an expression positive for Ki67 (B.1), while they showed an





Figure 2: Detection of the expression of ABL control gene mRNA (1), adiponectin (2), and leptin (3) through endpoint PCR in MCF-7 (a)
and HCC1937 (b) cells.
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proliferation in relation to leptin concentrations.With regard
to MCF-7 cells, the cell population decreased 64.71%
(1000ng/mL, 96 h), except at 1000 ng/mL, where it increased
30.77% after 72 h of stimulation. The cell growth of
HCC1937 decreased at all concentrations, up to 57.14%
(1000ng/mL, 24h) (Figure 4).
In relation to the cells that were subjected to the leptin
stimuli 48 h after culture (Group 2), a positive effect was
observed in cell proliferation with relation to leptin concen-
trations. With regard to MCF-7, the effect of this protein over
cell proliferation was positive, increasing by 28.57% (10ng/
mL, 48 h); this effect was maintained until 72 h, at a concen-
tration of 1000 ng/mL, where there was a 3.45% increase with
regard to the control. It was observed that for the concentra-
tion that corresponds to normal weight (10 ng/mL), the
positive effect of leptin was maintained until 48 h and
decreased by 6.90% with the third stimuli (72 h) and posteri-
orly presented an increase in the cell population once again at
96 h; not so for the concentration of 100ng/mL, where at 72 h
of stimulation, the cell population decreased by 26.68%. The
cell growth of HCC1937 decreased by 23.46% (1000ng/mL,
24 h), except after 72 h, at which all the concentrations
presented an increase in the cell population, up to 17.24%
(1000ng/mL), maintaining themselves until 96 h, where
there was an increase of 0.49% at 10ng/mL, 0.25% at
100ng/mL, and 10.31% at 1000 ng/mL with regard to the
control, indicating that the higher the concentration of lep-
tin, the higher the increase in cell population. It was observed
that, despite the fact that the cell population was maintained
above the control at all times and concentrations after 48 h of
stimulation, there was a gradual decrease of cells, as can be
seen in Figure 4.
4.4. Expression of AdipoR1 and AdipoR2 Mediated by Leptin
in Breast Cancer Cell Lines. The mRNA of AdipoR1 and
AdipoR2 was detected in MCF-7 and HCC1937 cell lines
through real-time PCR. The expression of AdipoR1 and
AdipoR2 in mRNA was determined in cells that were stimu-
lated with leptin at differential concentrations (0 ng/mL,
10 ng/mL, 100ng/mL, and 1000 ng/mL) in both cell lines.
In MCF-7, the expression of AdipoR1 had a decrease of
3.81% (1000 ng/mL) in the cells treated with leptin with
regard to the control, except for 100ng/mL, where there
was a 64.03% increase in the expression of the gene. How-
ever, the expression of AdipoR2 increased considerably in
the cells treated with leptin (up to 13.74 times; 10 ng/mL),
with regard to the control (Figure 5).
Analyzing the normalized values of treated cells in the
MCF-7 line, no statistically significant differences were found
in the expression of AdipoR1 between the controls and the
cells treated with differential concentrations of leptin:
10 ng/mL (p = 0 0945), 100 ng/mL (p = 0 760), and 1000 ng/
mL (p = 0 7840). However, upon analyzing the normalized
values of treated cells for the expression of AdipoR2, statisti-
cally significant differences were found between the controls
and the cells treated with differential concentrations of
leptin: 10 ng/mL (p = 0 0022), 100 ng/mL (p = 0 0022), and
1000 ng/mL (p = 0 0022) (Table 1).
In HCC1937, the expression of AdipoR1 decreased in
cells treated with leptin with regard to the control, as much
as 86.28% (10 ng/mL), while the expression of AdipoR2 had
a decrease in the cells treated with leptin with regard to the
control, as much as 50.3% (100 ng/mL), which can be seen
in Figure 5.
Analyzing the normalized values of treated cells in the
HCC1937 line, statistically significant differences were found
with regard to the controls for the expression of AdipoR1
in the cells treated: 10 ng/mL (p = 0 0043) and 1000 ng/mL
(p = 0 0130). For the cells treated with 100ng/mL of leptin,
no statistically significant differences were found for the
expression of AdipoR1. As for the expression of AdipoR2,
upon analyzing the normalized values of treated cells, no
statistically significant differences were found between the
controls and the cells treated with differential concentrations
of leptin: 10 ng/mL, 100 ng/mL, and 1000 ng/mL (Table 1).
5. Discussion
It has been determined that obesity and excess weight are risk





Figure 3: Detection of ACTB mRNA expression (1), AdipoR1 (2), and AdipoR2 (3) through endpoint PCR in MCF-7 (a) and
HCC1937 cells (b).
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(occidental and Asian) [45, 46]. The procarcinogenic effect
of leptin and the anticarcinogenic effect of adiponectin is
mainly due to two mechanisms: (1) modulation of signal-
ing pathways implicated in the proliferation process and
(2) subtle regulation of the apoptotic response [4].
The characterization of each cell line through the immu-
nohistochemistry technique was carried out according to the
molecular classification “triple negative” (MCF-7) and “triple
negative” (HCC1937), which allowed for the observation
that inMCF-7, the estrogen receptor presented an expression
9 times greater than the progesterone receptor and up to
3.21 times greater than Her2. HCC1937 presented a nega-
tive expression for RF, PR, and Her2, which corresponds
to that reported in the literature [47], in addition to the 7%
Ki67 expression.
The effect of leptin over cell growth has been determined
in MCF-7, MDA-MB231, SK-BR-3, T47D, and ZR-75-1
breast cancer cell lines, mediated by diverse signaling path-
ways when a single stimulus of the protein is applied and is
incubated between 24 and 96 h [21, 27, 37, 38, 48, 49]. In this
study, protein stimuli was applied every 24 h in order to emu-
late the constant secretion of the said protein by adipose
Time (h)


















































































Figure 4: Cell viability with leptin stimulation. The data is expressed in mean± SD, n = 3. Effect of leptin in MCF-7 breast cancer cells (a) at
application of the first stimuli 24 h after cell culture, (b) MCF-7 cells at application of first stimuli 48 h after cell culture, (c) HCC1937 cells at
application of first stimuli 24 h after cell culture, and (d) HCC1937 cells at application of first stimuli 48 hours after cell culture. ∗Significant
differences compared with the control (ANOVA test, p < 0 05).
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tissue in a condition of normal weight (10 ng/mL), excess
weight-obesity (100 ng/mL), and a very high concentration
of leptin (1000ng/mL).
In group 1 of the MCF-7 breast cancer cells, it was
observed that the effect of leptin over cell proliferation was
antiproliferative, decreasing up to 64.71%. It was also
observed that this antiproliferative effect is due to the sensi-
bility of the cells while being recultured (period of cellular
adaptation) and to the immediate administration of an exog-
enous agent, since despite that there was a decrease in the cell
population during the first stimulation with leptin (24 h), in
the posterior stimulations (48 and 72 h), there was a gradual
increase in cell population with regard to the population
obtained at 24h of stimulation. An increase of 0.65% and
9.50% for the concentration of 10ng/mL at 48h and 72 h,
an increase of 12.04% and 69.23% for 100ng/mL at 48h
and 72h, and an increase of 12.04% and 139.74% for
1000 ng/mL at 48 h and 72 h, respectively, were observed,
which indicate that the greater the concentration of leptin,
the greater the increase in cell population. Likewise, the cells
to which 4 stimuli of leptin were administered (96 h) showed
a major decrease in cell population with regard to the control
(10 ng/mL: 45.09%; 100 ng/mL: 56.86%; and 1000 ng/mL:
64.71%), possibly due to a saturation of the cell receptors
by leptin.
In the MCF-7 breast cancer cells of group 2, the effect of
leptin over cell proliferation was positive, increasing up to
28.57%, except for the concentration of 100ng/mL, in which
Leptin conc.
















































































Figure 5: Units of relative expression of AdipoR1 and AdipoR2. The data is expressed as mean± SD. In MCF-7 breast cancer cells, there is a
2.92% decrease in the expression of AdipoR1 (a) in cells treated with leptin (100 ng/mL) with regard to the control and of 3.81% for the
concentration of 1000 ng/mL, except at 10 ng/mL, where there was a 64.03% increase; the expression of AdipoR2 (b) increased by 13.74
times in cells treated with leptin (10 ng/mL) with regard to the control, 9.23 times for 100 ng/mL, and 11.39 times for 1000 ng/mL, finding
significant differences compared to the control in all concentrations. With regard to the HCC1937 breast cancer cells, the expression of
AdipoR1 (c) presented an 86.28% decrease in cells treated with leptin (10 ng/mL) with regard to the control, 13.72% (100 ng/mL), and
77.14% (1000 ng/mL), finding significant differences for 10 g/mL and 1000 ng/mL; the expression of AdipoR2 (c) exhibited a 24.4%
decrease in cells treated with leptin (10 ng/mL), with regard to the control, 50.3% (100 ng/mL), and 26.2% (1000 ng/mL); however, no
significant differences were found in any of the concentrations relative to control. ∗Significant differences compared to the control
(U of Mann–Whitney, p ≤ 0 05).
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at 72 h of stimulation, the cell population decreased up to
26.68% (10 ng/mL, 48 h) and was maintained until 72 h
at the concentration of 1000 ng/mL, where there was a
3.45% increase with regard to the control. This effect could
be due to the elimination of the cellular adaptation period,
since the cells were left to grow for another 24 h before the
addition of exogenous agent (leptin) to the medium,
allowing the cells to grow stronger, so as to not be damaged
by the protein.
In the HCC1937 breast cancer cells of group 1, the effect
of leptin over cell proliferation was negative at all concentra-
tions evaluated (57.14%). As in the case of the MCF-7 breast
cancer cells, it was observed that this antiproliferative effect is
due to the sensibility of the cells while being recultured and
the immediate administration of leptin; since despite a
decrease in the cell population during the first stimulation
with leptin (24 h), in the second, there was a small increase
in the population with regard to the cells obtained at 24 h
of stimulation: for the concentration of 10ng/mL, an increase
of 60%; for 100ng/mL, an increase of 40%; and for 1000 ng/
mL, an increase of 28.33%. However, this effect was not
maintained with posterior stimulations.
The aforementioned results demonstrate that the period
of cellular adaptation interferes with the effect of leptin over
MCF-7 and HCC1937 proliferation, in which the period of
cellular adaptation posterior to culture is between 2 and 3
days. In these cell lines, there was a positive effect over cell
proliferation at all concentrations administered, when the
first stimuli was administered 48 h after cell culture. Based
on these results, it was decided that a cell stimulation be done
with leptin 48 hours after cell culture.
An important find from the detection of leptin, adipo-
nectin, AdipoR1, and AdipoR2 mRNA in breast cancer
cells through endpoint PCR was that in HCC1937, a
triple-negative cell line with a mutation in BRCA1 [44],
these proteins and receptors are also found to be
expressed, information that had not been reported in the
literature. The aforementioned means that indistinctly of
the molecular classification of breast cancer to which the
cell lines belong, they can express leptin, adiponectin,
and its receptors, allowing for the possibility of a future
treatment for triple-positive breast cancer patients, patients
with negative breast cancer, and patients with triple-negative
breast cancer with mutations in BRCA1.
As for the expression assay, in MCF-7 breast cancer cells,
the expression of mRNA of AdipoR2 (2.423± 2.35) was
greater than the expression of AdipoR1 (1.679± 1.76). For
the stimulations with leptin, it was found that the expression
of AdipoR1 mRNA decreased with regard to the control in
the cells that received 100ng/mL and 1000ng/mL of up to
3.81%, while the cells that received a stimulus of 10 ng/mL
showed a 64.03% increase in expression. Surprisingly, the
expression of AdipoR2 mRNA was dramatically increased
at all concentrations of leptin: 10 ng/mL (13.75 times),
100 ng/mL (9.23 times), and 1000 ng/mL (11.39 times). Once
again, the concentration at which there was a greater increase
in the expression of the adiponectin receptor was at the “nor-
mal weight” concentration (10ng/mL), which could indicate
that in a condition of normal weight (10 ng/mL), at a high
level of AdipoR1 and AdipoR2, the adiponectin could suc-
cessfully carry out its antiproliferative activity of cancer
cells and, in this manner, generate a form of protection
for the patient.
The reduction in the expression of AdipoR1 in MCF-7
breast cancer cells corresponds with that proposed in the
hypothesis of the present work, since in cells that received
higher concentrations of leptin (100 ng/mL=excess weight-
obesity; 1000 ng/mL), a decrease in the expression of mRNA
of the gen was observed with regard to the control, while the
cells that received stimulation with a concentration corre-
sponding to normal weight showed an increase in the expres-
sion of both receptors. On the other hand, the increase in the
expression of AdipoR2 mRNA and the decrease in the cell
population at all concentrations at 96 h of stimulation could
indicate that the effective receptor for the in vivo signaling
of adiponectin in the breast cancer tissue is AdipoR2; this
corresponds to that found in 2009 by Jardé et al. [27].
Despite this evidence, the notion of the effective receptor
for adiponectin is uncertain, since it has been found that
when siRNA was used against AdipoR1, the antiproliferative
activity of adiponectin in T47D cells was annulated [30].
Likewise, studies have established a relationship between
the presence of AdipoR1 and a better diagnosis in gastric
and colon cancers [50, 51].
With regard to the expression of AdipoR1 and AdipoR2
mRNA in HCC1937 breast cancer cells, as in the case of
MCF-7 cells, the expression of AdipoR2 mRNA (1.336±
0.905) was greater than the expression of AdipoR1 (1.181±
0.67). However, contrary to that found in MCF-7, there was
a decrease in the expression of AdipoR1 mRNA of up to
86.26% (10ng/mL), when stimulated with leptin, and up to
50.3% (100 ng/mL) for the expression of AdipoR2 mRNA.
These results correspond to that found in cell viability curves
(Figure 4), where it can be seen, in a much more marked
manner, that there is a positive stimulation over cell prolifer-
ation at all concentrations of leptin employed due to the lack
of antiproliferative activity offered by adiponectin through its
receptors, generated from the decrease in the mRNA expres-
sion of these.
For HCC1937 cells, a part of the hypothesis proposed was
corroborated for AdipoR1 and AdipoR2, due to the fact that









10 2.754± 0.701 33.31± 16.006∗∗
100 1.63± 1.74 22.354± 14.006∗∗
1000 1.615± 1.209 27.607± 21.102∗∗
HCC1937
10 0.162± 0.129∗∗ 1.01± 0.755
100 1.019± 1.423 0.664± 0.502
1000 0.27± 0.27∗ 0.986± 0.597
2−ΔΔCT Relative expression using BACT as a constitutive gene. The data is
expressed as mean ± SD, n = 6. In statistical Mann–Whitney U test,
significance with regard to the control ∗p ≤ 0 05, ∗∗p ≤ 0 01.
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there was a decrease in the expression of mRNA in both cell
receptors in the cells that received stimulation from leptin
every 24 h. Contrary to what is expected, a greater decrease
of expression was found in concentrations corresponding
to normal weight (10 ng/mL) and excess weight-obesity
(100 ng/mL), which could indicate that in a condition of
excess weight and obesity, there is a blockage in the expres-
sion of these receptors, which leads to adiponectin not being
able to carry out its protective (antiproliferative) action
during the development of breast cancer.
In our study, one of the limitations found was that the
effect of leptin on cell proliferation and expression of Adi-
poR1 and AdipoR2 was modest, due to the range of leptin
concentrations used to perform the cellular stimulus was very
wide, which did not allow to identify exactly the effect that
this protein has on the gene expression of these receptors in
a state of obesity. On the other hand, it is impossible to
extrapolate the results obtained from leptin stimulation in
the cell lines with the results of expression that could be
obtained directly from obese patients with breast cancer
due to the complexity of the metabolic environment of the
tumor in vivo.
6. Conclusion
In this study, the effect of leptin over cell proliferation and
genic expression of AdipoR1 and AdipoR2 in MCF-7 and
HCC1937 cells was modest. Indistinctly of the molecular
classification of breast cancer of the cell lines used, they all
express leptin, adiponectin, AdipoR1, and AdipoR2. It was
determined that the period of cell adaptation generates an
interference with the effect of leptin over the proliferation
of MCF-7 and HCC1937 cells. During the development of
breast cancer, the capacity of proliferation (23.68% for
MCF-7 and 17.24% for HCC1937), explained by the deregu-
lation of leptin in obesity, could be very relevant at the
moment of prescribing a treatment to the patient. The
concentration of leptin that generated an increase in the
expression of both receptors of adiponectin was that corre-
sponding to normal weight (10 ng/mL), indicating that in
said condition, adiponectin can successfully carry out its
antiproliferative activity over cancer cells and, in this man-
ner, generate a form of protection for the patient.
The reduction in the expression of AdipoR1 mRNA and
the increase in the expression of AdipoR2 mRNA could
indicate that the effective receptor for the in vivo signaling
of adiponectin in breast cancer tissue is AdipoR1.
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